2021
The Impact of COVID‐19 on Organ Donation, Procurement, and Liver Transplantation in the United States
Merola J, Schilsky ML, Mulligan DC. The Impact of COVID‐19 on Organ Donation, Procurement, and Liver Transplantation in the United States. Hepatology Communications 2021, 5: 5-11. PMID: 33043228, PMCID: PMC7537114, DOI: 10.1002/hep4.1620.Peer-Reviewed Original ResearchLiver transplantationOrgan recoveryOrgan transplantationSevere acute respiratory syndrome coronavirus type 2End-stage liver diseaseOrgan donationExpected excellent outcomesLiver transplant recipientsCoronavirus disease 2019 (COVID-19) pandemicCoronavirus type 2Life-saving procedureCoronavirus disease 2019Disease 2019 pandemicOrgan procurement organizationsHealth care systemTransplant recipientsOrgan failureLiver diseaseDonor evaluationExcellent outcomesDisease 2019New practice paradigmHospital resourcesType 2Particular patient
2017
Inequity in organ allocation for patients awaiting liver transplantation: Rationale for uncapping the model for end-stage liver disease
Nadim MK, DiNorcia J, Ji L, Groshen S, Levitsky J, Sung RS, Kim WR, Andreoni K, Mulligan D, Genyk YS. Inequity in organ allocation for patients awaiting liver transplantation: Rationale for uncapping the model for end-stage liver disease. Journal Of Hepatology 2017, 67: 517-525. PMID: 28483678, PMCID: PMC7735955, DOI: 10.1016/j.jhep.2017.04.022.Peer-Reviewed Original ResearchConceptsEnd-stage liver diseaseLiver transplantMELD scoreLiver diseaseSick patientsLiver transplantationOrgan allocationEquitable organ distributionGreater MELD scoresPost-transplant outcomesOrgan Sharing dataPost-transplant survivalUnderwent liver transplantObjective scoring systemWaitlist registrationWaitlist mortalityHazard ratioSurvival benefitWaitlist candidatesUnited NetworkPatientsTransplantScoring systemMELDOrgan distribution
2016
The impact of broader regional sharing of livers: 2‐year results of “Share 35”
Edwards EB, Harper AM, Hirose R, Mulligan DC. The impact of broader regional sharing of livers: 2‐year results of “Share 35”. Liver Transplantation 2016, 22: 399-409. PMID: 26890858, DOI: 10.1002/lt.24418.Peer-Reviewed Original ResearchConceptsWaiting list mortalityLiver transplantLiver diseaseEnd-stage liver disease candidatesEnd-stage liver diseasePosttransplant survival outcomesChronic liver diseaseCold ischemia timeShare 35 policyRegional sharingBroader regional sharingPost-policy periodPosttransplant graftUrgent groupIschemia timePatient survivalSurvival outcomesMedian MELDMortality rateSickest candidatesOrgan procurementTransplantation NetworkTransplantAge groupsUrgent patients
2009
Natural history of post–liver transplantation hepatitis C: A review of factors that may influence its course
Gallegos‐Orozco J, Yosephy A, Noble B, Aqel BA, Byrne TJ, Carey EJ, Douglas DD, Mulligan D, Moss A, de Petris G, Williams JW, Rakela J, Vargas HE. Natural history of post–liver transplantation hepatitis C: A review of factors that may influence its course. Liver Transplantation 2009, 15: 1872-1881. PMID: 19938138, DOI: 10.1002/lt.21954.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdultBiopsyDisease ProgressionFemaleGraft RejectionHepatitis CHumansKaplan-Meier EstimateLiver CirrhosisLiver FailureLiver TransplantationLiving DonorsMaleMiddle AgedProportional Hazards ModelsRecurrenceRetrospective StudiesRisk AssessmentRisk FactorsSeverity of Illness IndexTime FactorsTreatment OutcomeConceptsEnd-stage liver diseaseHCV-positive recipientsLiver transplantHepatocellular carcinomaHCV recurrenceAcute rejectionPatient survivalBiopsy-proven acute rejectionMedian age 53 yearsHistory of HCCAggressive HCV recurrenceEarly acute rejectionProtocol liver biopsiesSignificant HCV recurrenceAdult liver transplantsAdvanced donor ageAge 53 yearsAge 39 yearsDay of transplantationLong-term survivalElectronic medical recordsAvoidance of rejectionEvaluable populationRapid fibrosersHepatitis CSclerosing peritonitis and mortality after liver transplantation
Mekeel K, Moss A, Reddy KS, Douglas D, Mulligan D. Sclerosing peritonitis and mortality after liver transplantation. Liver Transplantation 2009, 15: 435-439. PMID: 19326414, DOI: 10.1002/lt.21702.Peer-Reviewed Original ResearchMeSH KeywordsAbdominal PainAdultAscitesBacterial InfectionsCholestasisEndoscopy, Digestive SystemFatal OutcomeHumansIntestinal ObstructionLiver DiseasesLiver TransplantationMaleMalnutritionMiddle AgedParacentesisPeritonitisReoperationRisk FactorsSclerosisTomography, X-Ray ComputedTreatment OutcomeVascular DiseasesConceptsLiver transplantationBowel obstructionRefractory ascitesBacterial peritonitisEnd-stage liver diseasePartial small bowel obstructionMassive refractory ascitesSmall bowel obstructionEpisodes of peritonitisSpontaneous bacterial peritonitisTime of transplantationAbdominal painBiliary obstructionLiver diseasePeritoneal dialysisInferior venaPeritoneal surfaceFibrous peelPeritonitisPatientsTransplantationAscitesObstructionComplicationsEpisodes
2007
Coccidioidomycosis masked by symptoms of end‐stage liver disease in transplant candidates
Sachdev MS, Blair JE, Mulligan DC, Kusne S. Coccidioidomycosis masked by symptoms of end‐stage liver disease in transplant candidates. Transplant Infectious Disease 2007, 9: 153-155. PMID: 17462003, DOI: 10.1111/j.1399-3062.2007.00215.x.Peer-Reviewed Original Research
2006
Reduced Priority MELD Score for Hepatocellular Carcinoma Does Not Adversely Impact Candidate Survival Awaiting Liver Transplantation
Sharma P, Harper AM, Hernandez JL, Heffron T, Mulligan DC, Wiesner RH, Balan V. Reduced Priority MELD Score for Hepatocellular Carcinoma Does Not Adversely Impact Candidate Survival Awaiting Liver Transplantation. American Journal Of Transplantation 2006, 6: 1957-1962. PMID: 16771808, DOI: 10.1111/j.1600-6143.2006.01411.x.Peer-Reviewed Original ResearchConceptsDeceased donor liver transplantationHepatocellular carcinomaHCC candidatesCandidate survivalLiver transplantationMELD scoreStage T1Waiting listEnd-stage liver diseaseDonor liver transplantationT2 hepatocellular carcinomaOrgan allocation policyUNOS databaseLiver transplantLiver diseasePatient survivalUnited NetworkHCC patientsIncidence rateOrgan SharingSurvivalTransplantationCarcinomaDropout rateTime period
2004
New preservation solutions for use in liver transplantation
Mulligan D, Reddy K, Moss A. New preservation solutions for use in liver transplantation. Current Opinion In Organ Transplantation 2004, 9: 159-162. DOI: 10.1097/01.mot.0000127629.78517.06.Peer-Reviewed Original ResearchNew preservation solutionLiver transplantationPreservation solutionDonor liversClinical studiesEnd-stage liver diseasePartial liver graftsMainstay of treatmentOrgan preservation solutionsLiver graftsReperfusion injuryLiver diseaseMarginal organsWaiting listWisconsin solutionTransplantationExperimental modelContinuous perfusionIdentification of pathwaysLiverRecent findingsIschemiaNovel advancesCelsiorGraftHepatopulmonary syndrome after living donor liver transplantation and deceased donor liver transplantation: A single‐center experience
Carey EJ, Douglas DD, Balan V, Vargas HE, Byrne TJ, Moss AA, Mulligan DC. Hepatopulmonary syndrome after living donor liver transplantation and deceased donor liver transplantation: A single‐center experience. Liver Transplantation 2004, 10: 529-533. PMID: 15048796, DOI: 10.1002/lt.20127.Peer-Reviewed Original ResearchConceptsDeceased donor liver transplantationDonor liver transplantationHepatopulmonary syndromeLiver transplantationShunt fractionEnd-stage liver diseaseLiver transplant recipientsSingle-center experienceNormal pulmonary functionMean shunt fractionTransplant recipientsMean PaO2Pulmonary functionLiver diseaseSingle centerSupplemental oxygenNatural courseTransplantationHepatic regenerationSmall seriesPatientsLDLTPaO2SyndromeComplicationsLiver transplantation for hepatocellular carcinoma: The MELD impact
Sharma P, Balan V, Hernandez JL, Harper AM, Edwards EB, Rodriguez‐Luna H, Byrne T, Vargas HE, Mulligan D, Rakela J, Wiesner RH. Liver transplantation for hepatocellular carcinoma: The MELD impact. Liver Transplantation 2004, 10: 36-41. PMID: 14755775, DOI: 10.1002/lt.20012.Peer-Reviewed Original ResearchConceptsDeceased donor liver transplantationNew allocation policyHCC candidatesPerson yearsIncidence rateHepatocellular carcinomaLiver transplantationUNOS databaseEnd-stage liver diseaseT2 hepatocellular carcinomaDonor liver transplantationDropout rateDate of implementationHepatic decompensationNew MELDClinical deteriorationMELD scoreLiver diseaseStage T1United NetworkOrgan SharingWaiting listSurvivalTransplantationCarcinomaHepatitis C Virus Recurrence in Living Donor Liver Transplant Recipients
Rodriguez-Luna H, Vargas HE, Sharma P, Ortiz J, De Petris G, Balan V, Byrne T, Moss A, Mulligan D, Rakela J, Douglas DD. Hepatitis C Virus Recurrence in Living Donor Liver Transplant Recipients. Digestive Diseases And Sciences 2004, 49: 38-41. PMID: 14992432, DOI: 10.1023/b:ddas.0000011599.78222.9e.Peer-Reviewed Original ResearchConceptsDeceased donor transplantationHepatitis C virusLiver transplantationLDLT groupDonor liver transplant recipientsHepatitis C virus recurrenceEnd-stage liver diseaseHCV RNA titersLiver transplant populationLiver transplant recipientsIncidence of rejectionHistological recurrenceChronic hepatitisTransplant recipientsVirus recurrenceDonor transplantationTransplant populationHCV PCRLiver biopsyLiver diseaseAggressive recurrenceSingle pathologistC virusRNA titersInstitutional protocol
2003
Early results of targeted prophylaxis for coccidioidomycosis in patients undergoing orthotopic liver transplantation within an endemic area
Blair JE, Douglas DD, Mulligan DC. Early results of targeted prophylaxis for coccidioidomycosis in patients undergoing orthotopic liver transplantation within an endemic area. Transplant Infectious Disease 2003, 5: 3-8. PMID: 12791068, DOI: 10.1034/j.1399-3062.2003.00005.x.Peer-Reviewed Original ResearchConceptsOrthotopic liver transplantationLiver transplantationPositive serologic resultsCoccidioidal infectionSerologic resultsEndemic areasEnd-stage liver diseaseReactivation of coccidioidomycosisRisk of coccidioidomycosisLiver transplant candidatesEndemic fungal infectionProphylactic fluconazoleTransplant recipientsUniversal prophylaxisDisseminated diseaseTransplant candidatesImmunocompromised hostLiver diseaseRecurrent infectionsClose surveillancePositive historyPatientsProphylaxisTransplantationHigh mortality
2002
Thrombendvenectomy for Organized Portal Vein Thrombosis at the Time of Liver Transplantation
Molmenti EP, Roodhouse TW, Molmenti H, Jaiswal K, Jung G, Marubashi S, Sanchez EQ, Gogel B, Levy MF, Goldstein RM, Fasola CG, Elliott EE, Bursac N, Mulligan D, Gonwa TA, Klintmalm GB. Thrombendvenectomy for Organized Portal Vein Thrombosis at the Time of Liver Transplantation. Annals Of Surgery 2002, 235: 292-296. PMID: 11807371, PMCID: PMC1422428, DOI: 10.1097/00000658-200202000-00019.Peer-Reviewed Original ResearchConceptsPortal vein thrombosisGraft survival ratesTime of transplantationLiver transplantationVein thrombosisMale patientsFemale patientsLiver diseasePortal veinControl groupSurvival rateEnd-stage liver diseaseOrthotopic liver transplantOrthotopic liver transplantationFirst postoperative dayIntensive care unitLength of stayCryptogenic cirrhosisDaily aspirinPVT groupPVT patientsTacrolimus immunosuppressionLiver transplantTransplant recipientsPostoperative day
2001
Mayo end-stage liver disease (MELD) score: Causes of variablitity in patients with end-stage liver disease (ESLD)
Yousfi M, Douglas D, Malinchoc M, Mulligan D, Rakela J, Moss A, Harrison M, Balan V. Mayo end-stage liver disease (MELD) score: Causes of variablitity in patients with end-stage liver disease (ESLD). Gastroenterology 2001, 120: a371. DOI: 10.1016/s0016-5085(08)81846-x.Peer-Reviewed Original ResearchMayo end-stage liver disease (MELD) score: Causes of variablitity in patients with end-stage liver disease (ESLD)
YOUSFI M, DOUGLAS D, MALINCHOC M, MULLIGAN D, RAKELA J, MOSS A, HARRISON M, BALAN V. Mayo end-stage liver disease (MELD) score: Causes of variablitity in patients with end-stage liver disease (ESLD). Gastroenterology 2001, 120: a371-a371. DOI: 10.1016/s0016-5085(01)81846-1.Peer-Reviewed Original Research
2000
The effect of orthotopic liver transplantation on the QTc interval in patients with end-stage liver disease
Carey E, Mulligan D, Balan V, Harrison M, Rakela J, Douglas D. The effect of orthotopic liver transplantation on the QTc interval in patients with end-stage liver disease. The American Journal Of Gastroenterology 2000, 95: 2507. DOI: 10.1111/j.1572-0241.2000.02690.x.Peer-Reviewed Original Research
1995
A Comparison Of Treatment With Transjugular Intrahepatic Portosystemic Shunt Or Distal Splenorenal Shunt In The Management Of Variceal Bleeding Prior To Liver Transplantation
Abouljoud M, Levy M, Rees C, Diamond N, Lee S, Mulligan D, Goldstein R, Husberg B, Gonwa T, Klintmalm G. A Comparison Of Treatment With Transjugular Intrahepatic Portosystemic Shunt Or Distal Splenorenal Shunt In The Management Of Variceal Bleeding Prior To Liver Transplantation. Transplantation 1995, 59: 226-229. PMID: 7839445, DOI: 10.1097/00007890-199501270-00013.Peer-Reviewed Original ResearchConceptsTransjugular intrahepatic portosystemic shuntDistal splenorenal shuntIntrahepatic portosystemic shuntDSRS groupVariceal bleedingLiver transplantationSurgical shuntsSplenorenal shuntLiver diseasePortosystemic shuntTIPS groupRole of TIPSPrevious transjugular intrahepatic portosystemic shuntEnd-stage liver diseaseChild-Pugh C patientsIntraoperative hemodynamic measurementsSubsequent transplant procedureAdvanced liver diseaseLiver transplant candidatesLiver transplant recipientsRecurrent variceal bleedingGroup of patientsFirst-line managementBlood flow measurementsComparison of treatments